Board of Directors
Thomas E. Shenk, Ph.D.Chairman of the Board, James A. Elkins Jr. Professor, Department of Molecular Biology, Princeton University
Professor Thomas Shenk is the Chairman of the Board of MeiraGTx Ltd. He is the James A. Elkins Jr. Professor of Life Sciences in the Department of Molecular Biology at Princeton University. He is a virologist who has investigated gene functions and pathogenesis of adenovirus, a DNA tumor virus, and human cytomegalovirus, a member of the herpes family of viruses. Prof. Shenk is a member of the American Academy of Arts and Sciences, the U.S. National Academy of Sciences, the U.S. National Academy of Medicine and the American Philosophical Society. He is a past president of the American Society for Virology and the American Society for Microbiology, and served on the board of directors of Merck and Company for 11 years. Prof. Shenk currently serves as a board member of Forge Life Science, Kadmon Holdings and the Hepatitis B Foundation.
Alexandria Forbes, Ph.D.President and CEO, MeiraGTx
Dr. Alexandria Forbes is President and CEO of MeiraGTx. Previously, Dr. Forbes served as Senior Vice President of Strategic Operations and Chief Commercial Officer at Kadmon Corporation. Dr. Forbes spent 10 years as a healthcare investor at Sivik/Argus Partners. At Sivik Partners Dr. Forbes was responsible for investments in biotechnology, specialty pharmaceuticals and diagnostics, and was portfolio manager for the Sivik Global Life Science Fund, a long-biased public markets fund investing in biotechnology companies globally. Before entering the hedge fund industry, Dr. Forbes was a Human Frontiers/Howard Hughes postdoctoral fellow at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center, where her research focused on cytoplasmic determinants and cell signaling pathways involved in the migration, establishment and maintenance of germ line stem cells in Drosophila melanogaster. Prior to this, Dr. Forbes was a research fellow at Duke University, and also at the Carnegie Institute at Johns Hopkins University where she studied the role of the hedgehog gene and it’s signaling pathway in the Drosophila embryo and adult. Dr. Forbes received her Ph.D. in Molecular Genetics from Oxford University, UK and her M.A. in Natural Sciences from Cambridge University, UK.
Keith R. Harris, Ph.D.Head, Football Finance Group (FFG) and Non-Executive Director, Cooper Gay Swett & Crawford (CGSC)
Dr. Keith Harris is a London-based investment banker and financier with a 25-year career as a senior corporate finance and takeover advisor. Dr. Harris is currently Head of the Football Finance Group, which manages funding for football clubs across Europe. Dr. Harris also serves as Non-Executive Director of Cooper Gay Swett & Crawford (CGSC), one of the world’s largest global wholesale and reinsurance brokers. Dr. Harris previously served as Executive Chairman of Seymour Pierce Ltd upon its acquisition from Investment Management Holdings plc. Dr. Harris was Chairman of the Football League from 2000 to 2002 and Director of Wembley National Stadium from 2001 to 2007. Dr. Harris also served as chairman or non-executive director of a range of public and private companies including Halfords plc. Dr. Harris served as CEO of HSBC Investment Bank PLC from 1994 to 1999. Prior to HSBC, Dr. Harris served as CEO of Apax Partners Ltd from 1990 to 1994. Prior to Apax, Dr. Harris served as Managing Director and Head of International Corporate Finance at Drexel Burnham Lambert, and eight years as President at Morgan Grenfell in New York. Dr. Harris received his Bachelor’s degree in business and economics from the University of Bradford and a Ph.D. in economics in from the University of Surrey.
Ellen Hukkelhoven, Ph.D.Senior Analyst - Perceptive Advisors
Dr. Ellen Hukkelhoven is a Senior Analyst at Perceptive Advisors, a leading healthcare investment firm. Perceptive invests in highly innovative therapies aimed at the treatment of true unmet medical needs. The team is dedicated to supporting these companies throughout their entire life cycle. Since joining Perceptive in 2013, Ellen has spearheaded investments in long-term portfolio companies including Alnylam, Global Blood Therapeutics, Amicus, Tesaro, Blueprint Medicines, True North, and Myokardia. Prior to Perceptive, Ellen received her PhD in Cancer Biology from Memorial Sloan Kettering Cancer Center. During her tenure at MSKCC, she founded and built the life sciences division of InSITE, a top graduate fellowship program that helps early stage companies with their most pressing needs. Ellen graduated magna cum laude from Princeton University with degrees in molecular biology and finance.
Arnold J. Levine, Ph.D.Systems Biology Professor Emeritus, School of Natural Sciences at the Institute for Advanced Study, Princeton, NJ
Dr. Arnold Levine is a widely acclaimed leader in cancer research. In 1979, Levine and others discovered the p53 tumor suppressor protein, a molecule that inhibits tumor development. He established the Simons Center for Systems Biology at the Institute, which concentrates on research at the interface of molecular biology and the physical sciences: on genetics and genomics, polymorphisms and molecular aspects of evolution, signal transduction pathways and networks, stress responses, and pharmacogenomics in cancer biology. From 1998 to 2002, Dr. Levine served as President and CEO and Robert Harriet Heilbrunn Professor of Cancer Biology at The Rockefeller University. Prior to his post at Rockefeller, he was chairman of the Department of Molecular Biology at Princeton University (1984-1996), and, prior to that, Chair of the Department of Microbiology at the Stony Brook University Medical Center School of Medicine. Numerous distinctions include: American Association for Cancer Research Academy, Fellow; National Academy of Sciences, Member; Memorial Sloan-Kettering Cancer Center, Medal for Outstanding Contributions to Biomedical Research 2000; Keio University Medical Science Fund, Japan, Keio Medical Science Prize 2000; Albany Medical Center Prize in Medicine and Biomedical Research 2001; American Association for Cancer Research, Kirk A. Landon-AACR Prize for Basic Cancer Research 2008; Dart/NYU Biotechnology Achievement Award in Basic Biotechnology 2008; American Cancer Society, Medal of Honor 2009; Lars Onsager Medal 2012.
Joel S. Marcus, J.D.Chairman, CEO and Founder, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments
Mr. Joel Marcus is the Chairman, Chief Executive Officer, and Founder of Alexandria Real Estate Equities, Inc. (NYSE:ARE), an urban office REIT uniquely focused on urban, world-class collaborative science and technology campuses in AAA innovation cluster locations. Mr. Marcus co-founded Alexandria in 1994 as a garage startup with a business plan and $19 million in seed capital and has led its growth into a publicly traded, investment-grade REIT. Alexandria has a total market capitalization of approximately $13 billion and significant market presence in key locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle Park. In 1996, Mr. Marcus also founded Alexandria Venture Investments, the company’s strategic venture capital arm, which he currently leads with a focus on novel, breakthrough discoveries in biopharmaceuticals, diagnostics, research tools, agtech, digital health, and technology. In 2011, Mr. Marcus co-founded the renowned Alexandria Summit, an invitation-only gathering of the world’s foremost visionaries from the biopharmaceutical, medical, academic, financial, philanthropic, advocacy, and government communities, to address the most critical global healthcare challenges. Prior to co-founding Alexandria, Mr. Marcus had an extensive legal career specializing in corporate finance and capital markets, venture capital, and mergers and acquisitions, with a unique expertise in the biopharmaceutical industry. He was one of the principal architects of the Kirin-Amgen EPO joint venture in 1984. He was also a practicing certified public accountant and tax manager with Arthur Young & Co., where he focused on the financing and taxation of REITs. In addition to MeiraGTx, Mr. Marcus serves on the boards of Accelerator Corporation and AgTech Accelerator, for which he was one of the original architects and co-founders, Atara Biotherapeutics, Inc. (NASDAQ:ATRA), Biotechnology Innovation Organization (BIO), Foundation for the National Institutes of Health (FNIH), Friends of Cancer Research, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), MedBlue Incubator, Inc., Multiple Myeloma Research Foundation (MMRF), NYU Schack Institute of Real Estate, Partnership for New York City, and Yumanity Therapeutics, as well as on NAREIT’s 2017 Executive Board. Mr. Marcus is a recipient of the Ernst & Young Entrepreneur of the Year Award (Los Angeles – Real Estate). He was awarded his undergraduate and Juris Doctor degrees at the University of California, Los Angeles.
Neil MendozaChairman, Victoria Private Investment Office
Mr. Neil Mendoza is Chairman of Victoria Private Investment Office, a London-based investment advisory firm. Mr. Mendoza joined the board of the business in 2010, with a background of 30 years in finance and publishing, creating, owning and selling businesses. Mr. Mendoza is Founder of the custom marketing and publishing agency Forward, which became one of the leading independent contract publishers; it published magazines, children’s books and poetry books and specialized in international and multilingual publishing with corporate partners including IBM, Tesco and Patek Philippe & Co. Forward was sold to WPP plc in 2001. He is a non-executive director at the UK government Department of Culture, Media and Sport and a Commissioner of Historic England. Mr. Mendoza is also involved in the not-for-profit sector as Chairman of The Landmark Trust and The Prince’s Foundation for Children and the Arts. Mr. Mendoza is also deputy chairman of the Soho Theatre and recently judged the Laurence Olivier awards for theatre. Mr. Mendoza received his Master’s degree in geography from Oriel College, Oxford University.
Stuart Naylor, Ph.D.Chief Development Officer, MeiraGTx
Dr. Stuart Naylor is Chief Development Officer of MeiraGTx. From 2008 to 2013, Dr. Naylor was Executive Director and Chief Scientific Officer of Oxford BioMedica plc, one of the world’s first gene therapy companies, where he pioneered the development of the company’s ocular products. Prior to joining Oxford BioMedica in 1997, Dr. Naylor’s career focused on translational cancer research, initially at the Imperial Cancer Research Fund’s Central Laboratories in London and subsequently at the Institute of Cancer Research working in the areas of cytokine and tumor biology. Dr. Naylor has a first degree in microbiology and virology, a Master’s degree in Immunology, and earned a Ph.D. from the Imperial Cancer Research Fund laboratory studying ovarian cancer and cytokine biology.